Core Insights - Pharvaris is focused on developing oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][14] - The company outlined its strategic priorities for 2026, emphasizing long-term prophylaxis and on-demand treatment of HAE attacks [3][4] Clinical Development - The pivotal Phase 3 study, RAPIDe-3, demonstrated that deucrictibant significantly reduced the median time to onset of symptom relief to 1.28 hours compared to placebo (p<0.0001) [5] - Topline data from the CHAPTER-3 study, assessing deucrictibant for prophylactic treatment of HAE attacks, is expected in the third quarter of 2026 [4][5] - The NDA dossier for deucrictibant's on-demand treatment of HAE attacks is on track for filing in the first half of 2026 [4][5] Financial and Operational Updates - Pharvaris has an estimated cash runway into the first half of 2027, indicating strong financial management [4][11] - The company was added to the Nasdaq Biotechnology Index in December 2025, reflecting its compliance with market capitalization and trading volume requirements [11] Upcoming Events - Pharvaris will participate in several investor conferences and medical congresses in early 2026, showcasing its ongoing clinical studies and findings [8][10][12]

Company Overview - Pharvaris N.V. is a late-stage biopharmaceutical company focused on developing novel, oral bradykinin B2 receptor antagonists to address unmet needs in bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH) [1][5] - The company aims to provide injectable-like efficacy and placebo-like tolerability with the convenience of oral therapies for the prevention and treatment of bradykinin-mediated angioedema attacks [5] Recent Financial Activity - Pharvaris announced the closing of an upsized underwritten public offering of 9,562,500 ordinary shares, which includes the full exercise of an option by underwriters to purchase an additional 1,312,500 ordinary shares, along with pre-funded warrants to purchase 500,000 ordinary shares [1] - The gross proceeds from this offering amounted to approximately $201.2 million before deducting underwriting discounts, commissions, and other offering expenses [1] Clinical Development - Pharvaris is currently evaluating the efficacy and safety of its drug, deucrictibant, in pivotal Phase 3 studies for both the prevention of HAE attacks (CHAPTER-3) and the on-demand treatment of HAE attacks (RAPIDe-3) [5]